In the Boardroom
Refine Search
Biotechnology
US biotech major Gilead Sciences has promoted James Meyers, who joined the company back in 1996. 17 November 2016
Biotechnology
US biotech major Biogen has named two members to the executive management team of Bioverativ, its planned spin-off company focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders. 16 November 2016
Generics
Ireland-incorporated drugmaker Endo International today announced the appointment of two executive leadership team members. 7 November 2016
article
French drugmaker Ipsen (Euronext: IPN) has appointed Aymeric Le Chatelier as executive vice president and chief financial officer. 4 November 2016
Pharmaceutical
Immuno-oncology company PsiOxus Therapeutics may opt for an initial share offering in 2017, though the company is not looking to go public anytime sooner, chief executive John Beadle told The Pharma Letter in an exclusive interview. 4 November 2016
Pharmaceutical
Roche Pharmaceuticals Asia Pacific says that Dr Christiane Hamacher has assumed the role of head of Asia Pacific (APAC), joining Swiss pharma giant Roche’s global leadership team 1 November 2016
Biotechnology
French biotech firm Erytech Pharma today announced the appointments of Dr Alexander Scheer, as the company’s chief scientific officer and Jean-Sébastien Cleiftie, as chief business officer. 27 October 2016
Biotechnology
Kite Pharma’s today announced the appointment of Chris Nowers as its head of Europe. He will be based in London. 13 October 2016
Pharmaceutical
Swiss drug developer EffRx Pharmaceuticals today said it has named Lorenzo Bosisio appointed as chief executive effective July 1st, 2016. 12 October 2016
Pharmaceutical
The board of directors of the Swiss Galenica Group has designated Stefan Schulze, currently chief executive of group company Vifor Fresenius Medical Care Renal Pharma (VFMCRP), as chief operating officer and president of the executive committee of Vifor Pharma. 6 October 2016
Pharmaceutical
Astellas Pharma has appointed Steven Benner as senior vice president and therapeutic area head for oncology, and promoted Anne Keating to vice president of clinical science for oncology, within the company's development organization. 6 October 2016
Pharmaceutical
Santhera Pharmaceuticals has appointed Kristina Timdahl as chief medical officer and head of development and a member of the executive management with effect from January 1, 2017. 5 October 2016
Pharmaceutical
Mariano Balaguer has been named the chief financial officer of USA-based Taro Pharmaceutical Industries. 4 October 2016
Pharmaceutical
Robert Mulroy, the chief executive of USA-based Merrimack Pharmaceuticals has resigned after 17 years in the role as the company undergoes a major restructuring which will see its workforce cut by 22%. 4 October 2016
Pharmaceutical
UK pharma major GlaxoSmithKline today announced that Brian McNamara has been appointed chief executive of GSK’s Consumer Healthcare division effective immediately. 29 September 2016
Pharmaceutical
Denmark’s Bavarian Nordic has appointed Christopher Heery as chief medical officer of the company. 28 September 2016
Biotechnology
Anglo-Swedish drugmaker AstraZeneca has appointed David Goldstein as chief advisor for its ambitious genomics initiative. 28 September 2016
Biotechnology
Nordic biotech firm Swedish Orphan Biovitrum has appointed Milan Zdravkovic its new head of research and development (R&D). 27 September 2016
Pharmaceutical
Germany’s Merck KGaA has appointed Isabel De Paoli as chief strategy officer effective October 1, 2016. 26 September 2016
Generics
Ireland-incorprated drugmaker Endo International has named Paul Campanelli as president and chief executive, effective immediately. 23 September 2016
Biotechnology
US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
Anthony Harnden has been appointed as the new chair of the UK’s Medicine and Healthcare products Regulatory Agency (MHRA). 20 November 2024
Biotechnology
Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO). 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
Biotechnology
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
Pharmaceutical
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
Biotechnology
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Pharmaceutical
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze